April 26, 2021
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attention: | Division of Corporation Finance, Office of Life Sciences |
Ms. Abby Adams |
Re: | Chemomab Therapeutics Ltd. Registration Statement on Form S-3 File No. 333- 255249 |
VIA EDGAR
Dear Ms. Adams:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Chemomab Therapeutics Ltd. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-255249) of the Registrant (the “Registration Statement”) be accelerated so that the Registration Statement will be declared effective at 5:00 p.m., Eastern Time, on April 28, 2021, or as soon thereafter as may be practicable.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so confirm that event with our outside counsel, Mr. David S. Glatt of Meitar | Law Offices, by email at dglatt@meitar.com. The Company hereby authorizes Mr. Glatt to orally modify or withdraw this request for acceleration.
Sincerely, | |
/s/ Adi Mor | |
Adi Mor | |
Chief Executive Officer |
cc: | David S. Glatt, Adv., Meitar | Law Offices |